MedTrace Logo

Clinical Trial to Evaluate the Efficacy and Safety of YHP1701

NCT03103256 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2018-09-07

No results posted yet for this study

Summary

The purpose of this study is to determine superiority of YHP1701 comparing to each monotherapy in patient with hypertension and primary hypercholesterolemia.

Conditions

  • Hypertension and Hyperlipidemia

Interventions

DRUG

YHP1701

PO, Once daily (QD), 8 weeks

DRUG

YHR1703

PO, Once daily (QD), 8 weeks

DRUG

YHR1704

PO, Once daily (QD), 8 weeks

Sponsors & Collaborators

  • Yuhan Corporation

    lead INDUSTRY

Principal Investigators

  • Andrew Lee · Yuhan Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-17
Primary Completion
2018-04-30
Completion
2018-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03103256 on ClinicalTrials.gov